BiotechTube

Brexpiprazole + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritability Associated With Autism Spectrum Disorder (ASD)

Conditions

Irritability Associated With Autism Spectrum Disorder (ASD)

Trial Timeline

Oct 30, 2019 → Sep 9, 2022

NCT ID
NCT04174365

About Brexpiprazole + Placebo

Brexpiprazole + Placebo is a phase 3 stage product being developed by Lundbeck for Irritability Associated With Autism Spectrum Disorder (ASD). The current trial status is completed. This product is registered under clinical trial identifier NCT04174365. Target conditions include Irritability Associated With Autism Spectrum Disorder (ASD).

What happened to similar drugs?

1 of 4 similar drugs in Irritability Associated With Autism Spectrum Disorder (ASD) were approved

Approved (1) Terminated (0) Active (3)
✅Aripiprazole + PlaceboBristol Myers SquibbApproved
🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
🔄KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
🔄BrexpiprazoleLundbeckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04174365Phase 3Completed
NCT03257865Phase 3Completed
NCT03259555Phase 3Completed
NCT01670279Phase 1Completed

Competing Products

7 competing products in Irritability Associated With Autism Spectrum Disorder (ASD)

See all competitors
ProductCompanyStageHype Score
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
47
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
47
Aripiprazole + PlaceboBristol Myers SquibbApproved
43
BrexpiprazoleLundbeckPhase 3
37
JZP541Jazz PharmaceuticalsPhase 2
24
PimavanserinAcadia PharmaceuticalsPhase 2/3
27
Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 2/3
35